317 related articles for article (PubMed ID: 30594678)
1. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Banerjee S; Adhikari N; Amin SA; Jha T
Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
[TBL] [Abstract][Full Text] [Related]
2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
3. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
Adhikari N; Amin SA; Jha T
Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
[TBL] [Abstract][Full Text] [Related]
4. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
Hassan MM; Israelian J; Nawar N; Ganda G; Manaswiyoungkul P; Raouf YS; Armstrong D; Sedighi A; Olaoye OO; Erdogan F; Cabral AD; Angeles F; Altintas R; de Araujo ED; Gunning PT
J Med Chem; 2020 Aug; 63(15):8634-8648. PubMed ID: 32672458
[TBL] [Abstract][Full Text] [Related]
6. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
[TBL] [Abstract][Full Text] [Related]
9. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors.
Huang WJ; Wang YC; Chao SW; Yang CY; Chen LC; Lin MH; Hou WC; Chen MY; Lee TL; Yang P; Chang CI
ChemMedChem; 2012 Oct; 7(10):1815-24. PubMed ID: 22907916
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
13. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
14. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
Amin SA; Adhikari N; Jha T
Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
[TBL] [Abstract][Full Text] [Related]
15. Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
Banerjee S; Adhikari N; Amin SA; Jha T
J Biomol Struct Dyn; 2020 Mar; 38(5):1551-1564. PubMed ID: 31074329
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
[TBL] [Abstract][Full Text] [Related]
17. HDAC8: a multifaceted target for therapeutic interventions.
Chakrabarti A; Oehme I; Witt O; Oliveira G; Sippl W; Romier C; Pierce RJ; Jung M
Trends Pharmacol Sci; 2015 Jul; 36(7):481-92. PubMed ID: 26013035
[TBL] [Abstract][Full Text] [Related]
18. On the inhibition of histone deacetylase 8.
Estiu G; West N; Mazitschek R; Greenberg E; Bradner JE; Wiest O
Bioorg Med Chem; 2010 Jun; 18(11):4103-10. PubMed ID: 20472442
[TBL] [Abstract][Full Text] [Related]
19. HDAC8 as an emerging target in drug discovery with special emphasis on medicinal chemistry.
Rajaraman S; Balakrishnan R; Deshmukh D; Ganorkar A; Biswas S; Pulya S; Ghosh B
Future Med Chem; 2023 May; 15(10):885-908. PubMed ID: 37227732
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.
Wolff B; Jänsch N; Sugiarto WO; Frühschulz S; Lang M; Altintas R; Oehme I; Meyer-Almes FJ
Eur J Med Chem; 2019 Dec; 184():111756. PubMed ID: 31630054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
